Abstract
▪ Abstract Multiple observational studies suggest a marked reduction in risk of coronary heart disease (CHD) associated with postmenopausal estrogen use. A new meta-analysis presented here extends these results to estrogen plus progestin regimens. Although the findings from observational studies are strong and consistent, and there are several plausible mechanisms by which estrogen might reduce risk for CHD, most of the known biases would tend to exaggerate estrogen's benefit. Further, estrogen therapy clearly increases risk for endometrial hyperplasia and cancer, venous thromboembolic events and gallbladder disease, and long-term use probably also increases the risk of breast cancer. Therefore, until findings from randomized trials confirm and quantitate the benefit of estrogen therapy for prevention of CHD, we believe it should not be recommended to all postmenopausal women.
Keywords
EstrogenMedicineObservational studyRandomized controlled trialInternal medicineHormone replacement therapy (female-to-male)Hormone therapyGallbladder diseaseEndometrial cancerBreast cancerDiseaseEndometrial hyperplasiaHeart diseaseProgestinOncologyEndocrinologyPhysiologyCancerCarcinomaTestosterone (patch)Gallbladder
Affiliated Institutions
Related Publications
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women. All-cause mortality ...
Medroxyprogesterone Acetate Antagonizes Inhibitory Effects of Conjugated Equine Estrogens on Coronary Artery Atherosclerosis
Although estrogen replacement therapy is associated with reduced risk of coronary heart disease and reduced extent of coronary artery atherosclerosis, the effects of combined (e...
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
During an average follow-up of 4.1 years, treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postme...
The Effects of Estrogen and Selective Estrogen Receptor Modulators on Cardiovascular Risk Factors
A bstract : Raloxifene, a selective estrogen receptor modulator, favorably alters several markers of cardiovascular risk in healthy postmenopausal women. While many of its effec...
Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
Hormone therapy should probably be recommended for women who have had a hysterectomy and for those with coronary heart disease or at high risk for coronary heart disease. For ot...
Publication Info
- Year
- 1998
- Type
- review
- Volume
- 19
- Issue
- 1
- Pages
- 55-72
- Citations
- 591
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
591
OpenAlex
Cite This
Elizabeth Barrett‐Connor,
Deborah Grady
(1998).
HORMONE REPLACEMENT THERAPY, HEART DISEASE, AND OTHER CONSIDERATIONS.
Annual Review of Public Health
, 19
(1)
, 55-72.
https://doi.org/10.1146/annurev.publhealth.19.1.55
Identifiers
- DOI
- 10.1146/annurev.publhealth.19.1.55